Covidien Reports First-Quarter Results

Covidien Reports First-Quarter Results

  • Net sales up 5%; Medical Devices sales up 8%
  • First-quarter diluted GAAP earnings per share were $1.03; excluding specified items, adjusted diluted earnings per share were $1.10
  • Increasing fiscal 2013 net sales guidance in all segments

DUBLIN--(BUSINESS WIRE)-- Covidien plc (NYS: COV) today reported results for the first quarter of fiscal 2013 (October - December 2012). First-quarter net sales of $3.06 billion were 5% above the $2.90 billion reported in the comparable period a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by one percentage point.

First-quarter 2013 gross margin of 57.5% declined 1.2 percentage points from the 58.7% of the prior-year period. On an adjusted basis, excluding the specified items shown on the attached quarterly Non-GAAP reconciliations table, first-quarter 2013 gross margin of 57.5% was 1.3 percentage points below that of a year ago. The decline was largely due to unfavorable foreign exchange rate movement, partially offset by positive business mix and productivity improvements.

Selling, general and administrative expenses (SG&A) for the first quarter of 2013 were above those of the same period of the year before, reflecting expenses associated with recent acquisitions, as well as spending on growth initiatives, including investments to expand the Company's presence in emerging markets. Research and development (R&D) expense in the first quarter of 2013 represented 4.9% of net sales, versus 5.0% of sales in the first quarter of 2012.

In the first quarter of 2013, the Company reported operating income of $658 million, versus $636 million in the same period the year before. First-quarter 2013 adjusted operating income, excluding specified items on the attached table, was $686 million, compared with $705 million in the prior year. First-quarter 2013 adjusted operating income, excluding the specified items, represented 22.4% of sales, versus 24.3% of sales in the year-ago period.

The first-quarter 2013 effective tax rate was 19.2%, versus an effective tax rate of 16.7% in the first quarter of 2012. The first-quarter 2013 adjusted tax rate, excluding specified items on the attached table, was 18.0%, versus 17.4% in the first quarter last year.

Diluted GAAP earnings per share were $1.03 in the first quarter of 2013, versus $1.02 per share in the comparable quarter of 2012. First-quarter 2013 adjusted diluted earnings per share, excluding specified items on the attached table, were $1.10, versus $1.13 a year earlier.

"We're off to a very good start in fiscal 2013, with first-quarter results exceeding our expectations," said José E. Almeida, Chairman, President and CEO. "In our large Medical Devices segment, we continued to generate above-market growth in a number of key categories, including stapling, energy, airway and ventilation. We delivered very strong growth in emerging markets, as we realized the benefits of our recent substantial investments in these fast-growing regions.

"As a result of our strong performance in the first quarter, coupled with the recent U.S. FDA approval of generic CONCERTA® extended-release (ER) tablets, we are raising our revenue guidance for fiscal 2013," Mr. Almeida added. "For the remainder of the year, we plan to make incremental growth-driving investments in R&D and SG&A that should enhance our future growth. We remain confident that our robust pipeline of new products, sizable expansion opportunities in emerging markets and recent promising portfolio additions will enable us to meet the significant challenges of the global marketplace and to continue to deliver good operational growth."


Medical Devices sales of $2.13 billion in the first quarter were 8% higher than the $1.98 billion in the comparable quarter of last year. Operational sales growth was 9%, as foreign exchange rate movement reduced the quarterly sales growth rate by one percentage point. Operationally, first-quarter sales in Endomechanical were well above those of a year ago, paced by double-digit gains for stapling that were led by our innovative Tri-Staple™ reloads. In Soft Tissue Repair, sales growth reflected an increase for suture, mesh and mechanical fixation products. Energy registered a good sales advance, spurred by another double-digit quarterly increase for vessel sealing products. In Oximetry & Monitoring, operational sales rose at a strong double-digit pace, as higher sales of sensors and monitors were aided by the acquisition of Oridion. Airway & Ventilation sales were well ahead of those in the year-ago quarter, chiefly reflecting a double-digit increase for ventilators, primarily due to the acquisition of Newport Medical. Vascular products posted higher sales, fueled by exceptional gains for neurovascular products and a good performance by peripheral vascular products.

Pharmaceuticals sales of $489 million in the first quarter were essentially unchanged from last year's first-quarter sales of $490 million. Sales of Specialty Pharmaceuticals climbed sharply from those of a year ago, primarily due to the strong performance of EXALGO® (hydromorphone HCl) ER tablets and good growth for generic products that was aided by the launch of generic CONCERTA® ER tablets. Sales of Active Pharmaceutical Ingredients were below those of the prior year, largely attributable to customer order timing. Sales of Contrast Products declined sharply in the quarter, primarily reflecting difficult comparisons from a one-time order in the year-ago period and continued weakness in the United States. First-quarter sales of Radiopharmaceuticals were about even with those of the first quarter of the year before. The Company remains on track for the mid-2013 spin-off of the Pharmaceuticals business.

Medical Supplies first-quarter sales of $434 million were up 2% from the $424 million in the comparable quarter of 2012. Operational sales growth in the quarter was 3%, as foreign exchange rate movement reduced the quarterly sales growth rate by one percentage point. The increase was due to higher sales of both Nursing Care products, which were led by a double-digit gain for enteral feeding, and SharpSafety™ products.

In the first quarter of 2013, Covidien purchased approximately 4.4 million ordinary shares under its previously announced share buyback program.


Covidien has updated its fiscal 2013 guidance to reflect the recent U.S. FDA approval of generic CONCERTA®, the extension of the R&D tax credit and better operational performance thus far in the fiscal year. The Company now estimates that net sales in fiscal 2013 will be up 5% to 8%, including foreign exchange at current rates. This compares with prior guidance of a 3% to 6% sales increase in 2013. Net sales are now expected to be up 5% to 8% versus 2012 in the Medical Devices segment and up high single digits or better in the Pharmaceuticals segment. For Medical Supplies, 2013 net sales are now expected to be 1% to 3% above 2012. There is no change to the forecast for operating margin, excluding the impact of one-time items, which is still expected to be in the 22% to 23% range. The effective tax rate, excluding one-time items, is now expected to be in the 17.5% to 18.5% range, compared with prior guidance of 18% to 19%.

While the planned spin-off of the Pharmaceuticals business may have a somewhat dilutive effect on Covidien's 2013 guidance, the underlying operational strength of the business, coupled with the expected benefits from generic CONCERTA® ER tablets, will temper the expected dilution.


Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit to learn more about our business.

CONCERTA is a registered trademark of ALZA Corporation.


The Company will hold a conference call for investors today, beginning at 8:30 a.m. ET. This call can be accessed three ways:

  • At Covidien's website:
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 800-561-2693. For participants outside the U.S., the dial-in number is 617-614-3523. The access code for all callers is 83035324.
  • Through an audio replay: A replay of the conference call will be available beginning at 11:30 a.m. on January 25, 2013, and ending at 5:00 p.m. on February 1, 2013. The dial-in number for U.S. participants is 888-286-8010. For participants outside the U.S., the replay dial-in number is 617-801-6888. The replay access code for all callers is 90266221.


This press release contains financial measures, including operational growth, adjusted gross margin, adjusted operating income, adjusted earnings per share and adjusted operating margin, which are considered "non-GAAP" financial measures under applicable Securities & Exchange Commission rules and regulations.

These non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with generally accepted accounting principles. The Company's definition of these non-GAAP measures may differ from similarly titled measures used by others.

The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of Covidien's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Covidien's business.

Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.


Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or Company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, our ability to effectively introduce and market new products or keep pace with advances in technology, the reimbursement practices of a small number of large public and private insurers, cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations, intellectual property rights disputes, complex and costly regulation, including healthcare fraud and abuse regulations and the Foreign Corrupt Practices Act, manufacturing or supply chain problems or disruptions, rising commodity costs, recalls or safety alerts and negative publicity relating to Covidien or its products, product liability losses and other litigation liability, divestitures of some of our businesses or product lines, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, competition, risks associated with doing business outside of the United States, foreign currency exchange rates and environmental remediation costs. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the fiscal year ended September 28, 2012, and in subsequent filings with the SEC. We disclaim any obligation to update these forward-looking statements other than as required by law.

Covidien plc
Consolidated Statements of Income
Quarters Ended December 28, 2012 and December 30, 2011
(dollars in millions, except per share data)
Quarter EndedPercent ofQuarter EndedPercent of
December 28, 2012Net Sales December 30, 2011 Net Sales
Net sales$3,056100.0%$2,898100.0%
Cost of goods sold (1)1,300 42.51,197 41.3
Gross profit1,75657.51,70158.7
Selling, general and administrative expenses (1)94130.890731.3
Research and development expenses1494.91445.0
Restructuring charges, net8 0.314 0.5
Operating income65821.563621.9
Interest expense(51)(1.7)(51)(1.8)
Interest income20.160.2
Other income1 2 0.1
Income before income taxes61020.059320.5
Income tax expense117 3.899 3.4
Net income$493 16.1$494 17.0
Net income per share:
Weighted-average number of shares outstanding (in millions):
(1) Amortization expense of intangible assets is included in the following income statement captions in the amounts shown:
Cost of goods sold$48$39
Selling, general and administrative expenses16 12 
$64 $51 
Covidien plc
Non-GAAP Reconciliations
Quarters Ended December 28, 2012 and December 30, 2011
(dollars in millions, except per share data)
Quarter Ended December 28, 2012
SalesGross profit




Income before
income taxes

Net income(1)

earnings per

Restructuring and related charges, net (2)19930.01
Separation costs (3)1919160.03
Tax matters (4)    11 0.02
As adjusted$3,056 $1,757 57.5$686 22.4$638 $523 1.10
Quarter Ended December 30, 2011
SalesGross profit




Income before
income taxes

Net income(1)

earnings per

Restructuring and related charges, net (5)41818140.03
Legal charges (6)4747350.07
Separation costs (3)  4 4 4 0.01
As adjusted$2,898 $1,705 58.8$705 24.3$662 $547 1.13

(1) Adjustments are tax effected at the applicable local statutory tax rates.

(2) Includes $8 million in restructuring charges, net and $1 million of restructuring-related accelerated depreciation included in cost of goods sold.

(3) Represents costs incurred related to the separation of our Pharmaceuticals segment, which are included in selling, general and administrative expenses.

(4) Consists primarily of an adjustment to prior year deferred income tax assets, which are not subject to the tax sharing agreement with Tyco International and TE Connectivity.

(5) Includes $14 million in restructuring charges, net and $4 million of restructuring-related accelerated depreciation included in cost of goods sold.


Read Full Story
Scroll to continue with content AD
  • US
  • Globals
  • Currencies
S&P 5002,670.7134.751.32%
NIKKEI 22520,666.07263.801.29%
Hang Seng27,090.81335.181.25%
USD (PER EUR)1.14-0.00-0.22%
USD (PER CHF)1.01-0.00-0.14%
JPY (PER USD)109.770.570.52%
GBP (PER USD)1.29-0.01-0.85%
My Portfolio >
More to Explore